OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A. ("Company"), in continuity with the response to Official Letter No. 529/2021-SLS, issued by B3 - Brasil, Bolsa, Balcão ("B3") on April 20, 2021 and the Notice to the Market on May 19, 2021, hereby announces to its shareholders and to the market in general that the Company maintains no changes in the progress of matterss involving the possible production of vaccines against COVID-19, despite news published in the media about this subject.
Therefore, the Company reiterates that it remains wihtout sufficient and relevant information, data, characteristics and assessments of regulatory issues and investments on the subject that may impact an investor's decision to trade shares issued by it, and also states that its only official channel of information to the market on this matter is through its Investor Relations department.
Thus, the Company reinforces that it continues with its strategic planning focused on developing its product pipeline, which includes veterinary vaccines, and keeping its shareholders and the market in general duly informed of any developments in relation to this notice.
Cravinhos, July 28th, 2021.
MARCELO DA SILVA
Chief Finance and Investor Relations Officer
Attachments
Original document
Permalink
Disclaimer
Ourofino Saúde Animal Participações SA published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2021 15:23:16 UTC.
Ouro Fino Saude Animal Participacoes S.A., also known as Ourofino, is a Brazil-based company engaged in the animal health market business sector in Latin America. The Company manufactures veterinary products using scientific technology in the Company's laboratories. The Company's products are divided into six sectors: Wholesale, Birds, Cattle, Equine, Pet and Pigs. The Wholesale area is divided into four lines: Anti-Mastiticos, producing antibiotics killing bacteria and lumps; Antimicrobial, which focuses on the treatment of bacterial infectious diseases; Ectoparasiticides, concentrated on insect repellent products, and Endectocides, which is the treatment and control of internal and external diseases of cattle, sheep and swine parasites. There is also one additional line of products divided for additives, biological, inoculants, diagnostic kit, probiotics, silage and other supplements, among others.
OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A. 
